Alessandro Vannucchi

3 weeks ago | nature.com | Daniele Capitanio |Francesca R. Calledda |Manuela Moriggi |Niccolò Bartalucci |Alessandro Vannucchi |Alessandra Balduini

Correction to: Leukemia https://doi.org/10.1038/s41375-024-02354-z, published online 18 July 2024In this article the author’s name Niccolò Bartalucci was incorrectly written as Bartalucci Niccolò. The original article has been corrected. About this articleCapitanio, D., Calledda, F.R., Abbonante, V. et al. Correction: Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis. Leukemia (2025).

1 month ago | onlinelibrary.wiley.com | Carlo Brugnara |Alessandro Vannucchi |Ayalew Tefferi

• , “ As I Recall the Beginning of the American Journal of Hematology Forty Years Ago ,” American Journal of Hematology ( ): , https://doi.org/10.1002/ajh.24205. • , “ The American Journal of Hematology in 2007 ,” American Journal of Hematology , no. ( ): – , https://doi.org/10.1002/ajh.21160. • and , “ The American Journal of Hematology, 2011 and Beyond ,” American Journal of Hematology , no. ( ): 1, https://doi.org/10.1002/ajh.21951.

1 month ago | nature.com | Daniel A. Arber |Ayalew Tefferi |Alessandro Vannucchi |Tiziano Barbui

AbstractA lively discussion persists regarding the diagnostic criteria for essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV), particularly in relation to early/pre-fibrotic myelofibrosis (pre-PMF), a disease entity initially introduced in 2001 by the 3rd edition of the World Health Organization (WHO) classification. The definition and criteria used to diagnose pre-PMF have been progressively modified over time.

Nov 5, 2024 | nature.com | Tiziano Barbui |Alessandra Carobbio |Alessandro Vannucchi |Paola Guglielmelli |Alessandro Rambaldi |Naseema Gangat

AbstractWe analyzed the neutrophil-to-lymphocyte ratio (NLR) in 1508 patients with PV and found that those with an NLR ≥ 5 were generally older, had a longer disease history, and had higher cardiovascular risk factors, more arterial thrombosis, and more aggressive blood counts, indicating a more proliferative disease.

Jan 26, 2024 | onlinelibrary.wiley.com | Ayalew Tefferi |Alessandro Vannucchi |Tiziano Barbui

1 DISEASE CLASSIFICATION AND INCIDENCE Essential thrombocythemia (ET) is one of four Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasms (MPNs), which also include polycythemia vera (PV), primary myelofibrosis (PMF), and MPN, unclassifiable (MPN-U).1-3 In addition, about 15% of patients with ET or PV develop a PMF-like phenotype, over time, referred to as post-ET or post-PV MF.4 MPNs are included in the 2022 International Consensus Classification (ICC) category of myeloid...